Motif-specific phosphorylation affected by NO loading of SSRBCs
| . | . | Baseline (AA vs SSRBCs) . | Effect of NO loading in SSRBCs . |
|---|---|---|---|
| Protein description . | Modified peptide sequence . | Untreated SSRBCs vs AARBCs (P) . | NO-loaded epinephrine-treated SSRBCs vs sham-loaded epinephrine-treated SSRBCs (P) . |
| Protein 4.1 | RLS*THSPFR | 6-fold increase (.01) | 2.64-fold increase (.019) |
| Pyruvate kinase isozymes R/L | SWVSKS*QR | 0 | 1.70-fold increase (.012) |
| E3 ubiquitin-protein ligase UBR4 | TLSDVEDQKELASPVS*PELR | 0 | 1.85-fold increase (.018) |
| . | . | Baseline (AA vs SSRBCs) . | Effect of NO loading in SSRBCs . |
|---|---|---|---|
| Protein description . | Modified peptide sequence . | Untreated SSRBCs vs AARBCs (P) . | NO-loaded epinephrine-treated SSRBCs vs sham-loaded epinephrine-treated SSRBCs (P) . |
| Protein 4.1 | RLS*THSPFR | 6-fold increase (.01) | 2.64-fold increase (.019) |
| Pyruvate kinase isozymes R/L | SWVSKS*QR | 0 | 1.70-fold increase (.012) |
| E3 ubiquitin-protein ligase UBR4 | TLSDVEDQKELASPVS*PELR | 0 | 1.85-fold increase (.018) |
Fold change in phosphorylation for peptides as a function of NO loading of SSRBCs before epinephrine treatment are presented. Phosphorylation of all membrane proteins presented in the table was upregulated by NO loading of SSRBCs before epinephrine treatment. Phosphorylation sites are indicated by “*”. Data were generated by using blood samples from 4 different patients with SCD or 4 healthy donors.